Report contents
Industry landscape
I. Industry Map: Moderna’s Real Battlefield Is mRNA Respiratory Vaccines in High-Income Markets
Because Moderna sells a handful of products to a handful of national buyers, its moat question is decided less by brand marketing than by two structural forces: how many firms can viably make and license an mRNA vaccine, and how much pricing power remains once governments set the purchase terms.
1. Core Market: A Narrow Slice of Preventative Vaccines, Sold Country by Country
Moderna is a commercial-stage biotech that designs messenger RNA (mRNA) medicines, packages them in lipid nanoparticles (LNPs), and manufactures them in its own facilities. Revenue today comes almost entirely from prophylactic vaccines against respiratory viruses — primarily Spikevax (COVID-19) and mResvia (RSV) — plus a shrinking set of government supply agreements. The rest of the portfolio, including the individualized neoantigen therapy partnered with Merck, a cytomegalovirus vaccine, and rare-disease enzyme programs, remains pipeline rather than an addressable market with revenue.
The value chain runs from upstream inputs — nucleotides, enzymes, plasmid DNA, and specialty lipids — into mRNA drug substance, drug product, and fill-finish, then downstream to national immunization bodies, retail pharmacy chains, and wholesalers. Moderna has deliberately integrated much of the upstream and manufacturing step in-house, which matters because it removes third-party tolling bottlenecks but also loads fixed cost onto a volatile demand base.
The precise submarket is mRNA-based preventative vaccines for seasonal respiratory viruses in high-income countries. That is narrower than "vaccines" and much narrower than "biotech." The geographic boundary is national, not global: each jurisdiction runs its own approval, its own advisory recommendation (the CDC’s ACIP process in the United States, national ministries in Europe and Japan), and its own tender or negotiation. Price and volume are therefore set country by country, which turns what looks like one market into a stack of small national oligopolies sharing a common technology base.
Company disclosure supports this framing. Moderna’s Form 10-K for fiscal year 2025 (filed February 20, 2026) — the highest-reliability source available here, audited and filed with the SEC — reports revenue by product and by geography rather than as a single blended business, consistent with a company whose economics depend on a few national procurement decisions. The same filings show how violently that base has shrunk since the pandemic peak: product sales fell from roughly $18 billion in 2022 to about $3 billion in 2024 (company annual reports), a decline driven by lower COVID vaccination rates and policy-driven demand rather than by a new entrant taking share.
2. Competitive Landscape: Few Players, but Weak Pricing Power
The competitive set is small and dominated by large, diversified vaccine manufacturers. Market share figures below are best read as directional estimates from industry sources rather than audited numbers.
| Player | Key respiratory products | Competitive position |
|---|---|---|
| Pfizer / BioNTech | Comirnaty (COVID), Abrysvo (RSV) | Largest COVID franchise; deepest commercial and distribution reach |
| Moderna | Spikevax (COVID), mResvia (RSV) | Second COVID entrant at scale; pure-play mRNA; pushing combination flu/COVID |
| GSK | Arexvy (RSV), influenza | Largest vaccine company by revenue; no marketed mRNA COVID product |
| Sanofi | Influenza, Beyfortus (RSV, with AstraZeneca) | Long-standing influenza leader; partnered with Novavax on COVID |
| Novavax | Nuvaxovid (protein-based COVID) | Small share; protein alternative rather than mRNA competitor |
| CSL Seqirus / AstraZeneca | Influenza | Entrenched seasonal influenza incumbents |
Applying the practical "can the leaders be counted on one hand" test, the answer is largely yes at the technology layer: only a very small number of firms worldwide hold approved mRNA respiratory vaccines at commercial scale, and far fewer have the manufacturing footprint and regulatory history to serve multiple high-income markets simultaneously. That implies meaningful barriers to entry — clinical development costs, regulatory precedent, LNP and mRNA chemistry patents, cold-chain logistics, and the capital required to build mRNA capacity.
But the structure has an unusual flaw. Entry barriers are high while buyer concentration is extreme. National health systems are near-monopsonists, demand is shaped by advisory recommendations rather than consumer preference, and volumes are seasonal and policy-dependent. The result, visible in Moderna’s post-2022 revenue collapse, is that a three-firm structure did not translate into durable pricing power. Replicability compounds this: CureVac, Arcturus, and other programs have shown the mRNA platform itself is not uniquely ownable, so the constraint on new entrants is commercial viability, not technical possibility.
Conclusion for Part I: Moderna competes in a high-barrier, narrow-participant vaccine oligopoly with a genuinely differentiated platform — yet one where demand is politically administered and pricing power is structurally capped. That combination is only partially favorable and sets up the moat question examined next.
Competitive advantage
II. Moat Verdict: Moderna's Oligopoly Structure Without Oligopoly Profits
1. The Right Starting Point: Concentration Plus Sustained Excess Returns
The essence of a competitive advantage is sustainably above-normal returns protected by barriers to entry. Two observable signals reveal whether that exists. First, high and stable market concentration suggests new entrants are being kept out. Second, sustained excess profitability shows the incumbent's edge is structural rather than a temporary run of good execution. Greenwald's warning matters here: high profits alone do not equal a moat. When many firms in an industry are highly profitable at once, success is more likely operational — and imitable — than structural.
For Moderna the two signals point in opposite directions. The industry is concentrated, but it is not profitable. That combination is the central fact of this analysis, and it is not a cyclical accident: it flows from a buyer structure that extracts the surplus concentration would otherwise protect.
2. Market Position and Stability
Market share and industry ranking — rating: Moderate. In the core submarket of mRNA vaccines for seasonal respiratory viruses in high-income countries, Moderna is the No. 2 supplier, not the leader. In COVID-19 vaccines it sits behind Pfizer/BioNTech's Comirnaty, with US dose share running in the mid-30s to low-40s percent range since 2021, based on third-party vaccination and dose-distribution tallies (directional estimates, not audited figures). In RSV, mResvia entered a market led by GSK's Arexvy and Pfizer's Abrysvo and holds only a marginal position. Second place in a two-supplier class, plus a negligible position in the adjacent category, is a real but not dominant franchise. Rating: Moderate.
Stability and trend of position — rating: Moderate. Moderna's share versus Pfizer/BioNTech has moved within a narrow band over five years, which by the book's benchmark — a shift of less than about 5 percentage points implies meaningful barriers — would ordinarily read as stability. The stability is misleading in one important way: the pool being shared collapsed. Product revenue fell from $18.9 billion in FY2022 to $1.9 billion in FY2025, a roughly 90% decline driven by falling vaccination rates and policy rather than by a rival taking share. Moderna also failed to establish a foothold in RSV or seasonal flu. The position has been stable in relative terms and deteriorating in absolute terms.
3. Profitability and Quality of Returns
Core return metrics — rating: Weak. Moderna's commercial history is short, so a ten-year average is not the right test; what matters is the shape of returns since products launched. Using return on equity (ROE) because the balance sheet is almost debt-free and ROE is directly computable from filings:
| Fiscal year | Revenue ($bn) | Gross margin | Net income ($bn) | ROE |
|---|---|---|---|---|
| FY2021 | 17.74 | 85% | 12.20 | 86% |
| FY2022 | 18.88 | 71% | 8.36 | 44% |
| FY2023 | 6.85 | 32% | -4.71 | -34% |
| FY2024 | 3.20 | 54% | -3.56 | -33% |
| FY2025 | 1.94 | 56% | -2.82 | -33% |
That is a five-year average of roughly 6%, squarely inside Greenwald's 6%-8% band that signals no competitive advantage — and the trailing three years are deeply negative. Estimated ROIC, calculated here as after-tax EBIT over invested capital, moves the same way: strongly positive in FY2022, deeply negative in each of FY2023 through FY2025. The cumulative picture is telling: roughly $9.5 billion of net income earned across FY2021-FY2025 came entirely from the two pandemic years, and the $2.1 billion of losses in the first half of FY2026 have already consumed about a fifth of it. Cash fell from $6.85 billion at FY2021 to $1.72 billion at Q2 FY2026, and equity from $14.1 billion to $6.8 billion. Diversified rivals such as Pfizer, GSK, and Sanofi earn positive returns across broad portfolios; Moderna's recent economics look closer to a single-product biotech than to an oligopoly member.
Revenue scale and margin profile — rating: Weak. Gross margin recovered to about 56% in FY2025 after the FY2023 trough of 32%, but net margin deteriorated further, to about -145%. On FY2025 revenue of $1.94 billion, gross profit of $1.08 billion left an operating loss of $3.07 billion — implying a fixed operating cost base of roughly $4.2 billion (author calculation from reported figures). That is the signature of a business whose fixed costs were built for pandemic-scale volume that no longer exists. Relative scale is modest: Moderna's annual revenue is a small fraction of Pfizer's, GSK's, or Sanofi's vaccine revenue.
4. Overall Rating and Core Rationale
Overall rating: Weak. Moderna does not currently demonstrate a durable competitive advantage.
- What the evidence shows: the industry is concentrated — only a handful of firms hold approved mRNA respiratory vaccines at commercial scale — yet concentration has not produced protected profits for Moderna.
- Why that matters: a five-year average ROE of about 6% sits in the "no advantage" range, three consecutive years are loss-making, and cash and equity are shrinking.
- Why the ranking does not rescue the rating: second place in a market that shrank roughly 90%, where the buyer sets price, is not a position that defends economics.
- Why not "None": high clinical, regulatory, and manufacturing hurdles are real, and a genuine No. 2 position in a two-supplier class is more than nothing — but the returns the firm captures do not reflect them.
III. Moat Anatomy: Regulatory Friction Is Real, Platform Strength Is Replicable
1. Why These Lenses Fit mRNA Vaccines
Four lenses matter for a vaccine maker and map directly onto how value is created and lost here. Supply-side advantage asks whether the company owns a process or input rivals cannot copy — the mRNA/LNP platform and manufacturing know-how. Demand-side advantage asks whether payers and patients are locked in, the critical question when the buyer is a national health system rather than a consumer. Economies of scale asks whether high fixed costs plus relative share create a cost barrier. Government and regulatory barriers ask whether licensure and procurement protect the incumbent. Greenwald's key combination — scale reinforced by customer captivity — is precisely the test that decides durability.
2. Supply-Side Advantage: Integrated mRNA Manufacturing and LNP Know-How — Weak
Logic chain:
What the company built. Moderna owns mRNA drug substance and drug product manufacturing, developed its own lipid-nanoparticle delivery chemistry, and designed facilities intended to scale quickly. During the pandemic this vertical integration looked powerful: it removed third-party manufacturing bottlenecks and let the company move from sequence to clinical supply unusually fast.
Why the advantage does not hold. The durability tests fail on three counts. First, the foundational intellectual property is not exclusively owned; key LNP and modified-nucleoside chemistry has been licensed and litigated rather than invented behind a sealed door, so rivals can access similar tools. Second, the technology has already been replicated at commercial scale — Pfizer/BioNTech reached mRNA COVID supply at comparable or larger volumes, and other developers showed that mRNA and LNP delivery are not uniquely ownable. Third, process know-how is learnable: modular plant design, cold-chain logistics, and purification methods are purchasable with capital and engineering talent.
What remains. Moderna retains a genuine speed-and-cost edge in scaling mRNA production, and its accumulated process data shortens development cycles. That is a real operating capability, but it does not stop a determined entrant and does not confer pricing power on its own. Replicable technology is the classic false moat. Rating: Weak.
3. Demand-Side Advantage: Customer Captivity — None
Logic chain:
Who actually buys. Moderna's customer is not a loyal consumer. In most high-income markets the volume decision is made by a national immunization body, a health ministry, or a pharmacy chain acting on a recommendation, and the price is negotiated rather than posted.
Switching costs are close to zero. A patient receives whichever vaccine is stocked at the counter at no meaningful cost difference and has no reason to prefer one mRNA shot. A national buyer is not captive either: contracts expire, tenders are re-run, and the purchase decision can be reversed by a single advisory-body vote. Search costs are low because regulators publish comparative efficacy and safety data, effectively performing the evaluation for the buyer.
No network effects. Vaccination does not become more valuable to one patient because another is vaccinated — herd protection is a public good, not a private lock-in.
Price sensitivity is extreme. With a near-monopsonist buyer and a product largely undifferentiated at the point of use, the company cannot hold price against a lower-cost alternative. Moderna has high brand awareness, but brand without captivity is not a moat; it did not prevent a roughly 90% revenue decline. Rating: None.
4. Economies of Scale: Fixed Costs Without Relative Dominance — Weak
Logic chain:
The cost structure is heavily fixed. Biologics manufacturing capacity, cold chain, clinical development, and regulatory affairs are largely fixed. On FY2025 figures, roughly $4.2 billion of operating cost was incurred against $1.94 billion of revenue, so cost absorption depends entirely on volume.
Relative share, not absolute size, decides the advantage. Moderna is the second supplier in a two-firm mRNA COVID class and a distant follower in RSV. Pfizer, the leader, spreads development, manufacturing, and commercial costs across a much larger vaccine portfolio, lowering its unit cost. The scale advantage in this market sits with the leader, not with Moderna. Minimum efficient scale and capital intensity do raise the cost of entry, but they raise it for everyone and do not by themselves block a well-funded competitor.
The critical combination is missing. Greenwald's test is scale reinforced by customer captivity. Without captivity, an entrant with capital can build capacity and bid for the same government contracts, because no buyer is locked in.
The evidence cuts against a scale moat. If Moderna held a scale advantage, falling volume would compress margins only at the edge. Instead, FY2025 revenue fell while operating losses persisted at roughly $3 billion, and revenue fell further in the first half of FY2026. That is the signature of an underutilized fixed base, not a cost moat. Rating: Weak.
5. Regulatory and Procurement Barriers: Real Friction, Capped Economics — Moderate
Logic chain:
How the barrier works. A vaccine cannot be sold without a biologics license supported by large late-stage trials, validated manufacturing, and continuing safety surveillance. In the United States, biologics exclusivity gives an approved product a protected window. Governments reinforce this by pre-committing to volumes through advance purchase agreements, effectively converting approval in a country into a license to supply it.
Why this is the strongest of Moderna's sources. Getting an mRNA vaccine approved and manufactured at scale across multiple high-income markets is a multi-year, capital-intensive undertaking, and only a small number of firms have done it. Clearing that hurdle gave Moderna a launch platform most competitors could not assemble on the same timeline.
Why it still rates only Moderate. First, the same government that licenses also sets the price, so monopsony power caps the return the barrier can protect. Second, the barrier protects the right to sell, not the price at which you sell, and a change in recommendation policy or procurement can reset volume almost overnight — which is what happened after 2022. Third, it did not actually exclude competitors: Pfizer/BioNTech, GSK, Sanofi, and Novavax all crossed the same regulatory threshold, so it raised the cost of entry without preserving the profit pool. Fourth, platform chemistry patents are partly licensed or aging, so the IP layer is weaker than it appears. Rating: Moderate, with high policy risk.
6. Durability: Substitutes and the False-Moat Test
Substitute threats set the ceiling on any moat, and here the ceiling binds from several directions.
- Product substitutes. Protein-based COVID vaccines such as Novavax's Nuvaxovid solve the same job without mRNA. In RSV and influenza, adjuvanted protein vaccines are the entrenched incumbents, making Moderna the challenger rather than the protected player.
- Demand reallocation. If recommendations move toward individual choice, the relevant substitute for many people becomes no vaccination at all — the cheapest alternative removes the purchase entirely.
- Treatment substitutes. Antiviral therapies compete with prevention for the same health budget in higher-risk populations.
- Cross-price sensitivity. National buyers negotiate hard and re-tender routinely, so pricing power is structurally constrained.
Applying the false-moat screen: the mRNA "platform" narrative is replicable technology; the pandemic cash reserve was deep pockets, not a barrier; the Moderna brand is recognition without captivity. None of these keeps rivals out or protects profits over time.
Conclusion: Moderna's only durable barrier — regulatory and procurement friction — is real but capped by monopsony buyers, substitute products, and policy risk. The platform is a genuine operating capability that shortens development and adds flexibility, but it is imitable. Moderna executes well in a structurally open field; the evidence does not support a protected profit pool.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow Moderna Inc compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Moderna Inc
Moderna Inc
Business, moat and key questions
Open company page